Project 3 has developed new approaches for targeting brain tumors using lipidic nanoparticle-based drugs, ncluding novel liposomes and immunoliposomes. These advances include: new and extremely robust technologies for drug loading and stabilization, resulting in novel nanoliposomal drugs that can deliver a number of anticancer compounds to brain tumors;antibody-targeted constructs (immunoliposomes) against EGFR and/or EGFRvlll;the first successful demonstration of convection-enhanced delivery (CED) of lipidic nanoparticles in the CMS;and imaging of drug delivery using CED of liposomal gadolinium (Gd). One of these novel agents, nanoliposomal CPT-11, has shown highly promising preclinical efficacy and has entered clinical trials as a systemic treatment. Using a clinically validated liposome-based scaffold, we can engineer additional capabilities to generate innovative and multifunctional nanoparticles for targeted delivery of anticancer drugs, either by systemic or CED routes. We now hypothesize that CED of lipidic nanoparticle- based agents combining drug delivery with imaging capability can provide targeted therapy of brain tumors. Our ongoing studies infusing lipidic nanoparticles into the brain via CED have exceeded our expectations as a robust and clinically applicable approach for the treatment of brain tumors, including the potential for targeting via MRI guidance. Accordingly, we will develop multifunctional nanoparticle-based systems for integrated image-guided therapy, combining encapsulated drugs and MRI probes and optimized for CED infusion to brain tumors.
Our Aims i nclude: 1) Develop lipidic nanoparticle/CED imaging strategy via co- infusion system or multifunctional nanoparticles co-encapsulating Gd + drug;2) Evaluate other lipidic nanoparticle agents in conjunction with image-guided CED, including other cytotoxic drugs and siRNA;3) Evaluate immunoliposome targeting combined with CED;and 4) Translate """"""""best"""""""" multifunctional lipidic nanoparticle agent/strategy to clinical trial. Lay summary: We are studying new approaches to deliver drugs more efficiently to brain tumors using nanoparticle agents (sub-microscopic carriers of drugs). We propose to infuse these particles directly into the brain to target brain tumors, and will use MRI to guide this treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097257-09
Application #
8099450
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
9
Fiscal Year
2010
Total Cost
$268,638
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Luks, Tracy L; McKnight, Tracy Richmond; Jalbert, Llewellyn E et al. (2018) Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. Transl Oncol 11:941-949
Viswanath, Pavithra; Radoul, Marina; Izquierdo-Garcia, Jose Luis et al. (2018) 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Res 78:2290-2304
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Mancini, Andrew; Xavier-Magalhães, Ana; Woods, Wendy S et al. (2018) Disruption of the ?1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell 34:513-528.e8
Disney-Hogg, Linden; Sud, Amit; Law, Philip J et al. (2018) Influence of obesity-related risk factors in the aetiology of glioma. Br J Cancer 118:1020-1027
Goode, Benjamin; Mondal, Gourish; Hyun, Michael et al. (2018) A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun 9:810
Takahashi, Hannah; Cornish, Alex J; Sud, Amit et al. (2018) Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Sci Rep 8:2339
Amirian, E Susan; Ostrom, Quinn T; Armstrong, Georgina N et al. (2018) Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis. Cancer Epidemiol Biomarkers Prev :
Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7
Disney-Hogg, Linden; Cornish, Alex J; Sud, Amit et al. (2018) Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med 16:42

Showing the most recent 10 out of 362 publications